Jeffrey Moy Sells 4,601 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

Share on StockTwits

DexCom, Inc. (NASDAQ:DXCM) SVP Jeffrey Moy sold 4,601 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $149.85, for a total value of $689,459.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

DXCM traded up $1.46 during trading on Wednesday, reaching $146.70. 911,812 shares of the company were exchanged, compared to its average volume of 1,200,108. DexCom, Inc. has a 12-month low of $105.05 and a 12-month high of $178.45. The company’s 50-day moving average is $160.01 and its two-hundred day moving average is $139.33. The company has a quick ratio of 5.64, a current ratio of 6.05 and a debt-to-equity ratio of 1.56. The company has a market cap of $13.26 billion, a price-to-earnings ratio of 489.00 and a beta of 0.72.

DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, July 31st. The medical device company reported $0.08 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.07. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. The business had revenue of $336.40 million during the quarter, compared to analyst estimates of $304.40 million. During the same quarter in the previous year, the firm earned ($0.10) EPS. The company’s quarterly revenue was up 38.7% compared to the same quarter last year. Equities analysts forecast that DexCom, Inc. will post 0.94 earnings per share for the current year.

Several research analysts have recently weighed in on the company. JPMorgan Chase & Co. increased their price target on DexCom from $170.00 to $190.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Zacks Investment Research cut DexCom from a “buy” rating to a “hold” rating and set a $163.00 price objective on the stock. in a research note on Monday, August 12th. Bank of America upped their price objective on shares of DexCom from $162.00 to $185.00 and gave the company a “buy” rating in a report on Thursday, August 1st. TheStreet upgraded shares of DexCom from a “d+” rating to a “c” rating in a research report on Friday, June 28th. Finally, BMO Capital Markets increased their target price on shares of DexCom from $180.00 to $190.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 3rd. Six research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $168.44.

Hedge funds have recently added to or reduced their stakes in the company. Gradient Investments LLC bought a new stake in DexCom during the 2nd quarter worth approximately $25,000. Virtus ETF Advisers LLC purchased a new stake in DexCom in the 2nd quarter worth approximately $29,000. Steward Partners Investment Advisory LLC purchased a new stake in DexCom in the 2nd quarter worth approximately $31,000. CSat Investment Advisory L.P. bought a new position in DexCom in the 2nd quarter valued at $31,000. Finally, Private Ocean LLC bought a new position in DexCom in the 1st quarter valued at $36,000. Institutional investors own 96.79% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Article: Support Level

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.